tak 779 has been researched along with HIV Infections in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (61.90) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Baba, M; Miyake, H; Okamoto, M; Takashima, K; Wang, X | 1 |
| Ballweber, L; Fialkow, M; Hladik, F; Kreger, A; Lentz, G; McElrath, MJ; Robinson, B; Sakchalathorn, P; Terker, A | 1 |
| Ajasin, D; Donoso, M; Eugenin, EA; Gorantla, S; Luu, R; Okafo, G; Prideaux, B; Valdebenito, S | 1 |
| Arakelyan, A; Chernomordik, LV; Margolis, LB; Marin, M; Melikov, K; Melikyan, GB; Villasmil, R; Zaitsev, E; Zaitseva, E | 1 |
| Arenzana-Seisdedos, F | 1 |
| Antonsson, L; Gisslén, M; Hagberg, L; Jansson, M; Karlsson, U; Kidd-Ljunggren, K; Ljungberg, B; Medstrand, P; Owman, C; Repits, J; Svennerholm, B | 1 |
| Henrich, TJ; Konstantinidis, I; Kuritzkes, DR; Leopold, KE; Lewine, NR; Sagar, M; Tsibris, AM | 1 |
| Bhattacharya, J; Gharu, L; Ringe, R | 1 |
| Coakley, E; Greaves, W; Gulick, RM; Henrich, TJ; Hu, Z; Kuritzkes, DR; Lee, SH; Putcharoen, O; Tsibris, AM; Vanichanan, J | 1 |
| Antunes, F; Barroso, H; Bártolo, I; Borrego, P; Caixas, U; Calado, R; Cavaco-Silva, P; Doroana, M; Maltez, F; Marcelino, JM; Rocha, C; Taveira, N | 1 |
| Chen, L; Chen, Z; Cheung, AK; Kang, Y; Lau, TC; Li, B; Li, S; Liang, J; Liu, L; Lu, X; Ng, J; Tan, Z; Wang, H; Wu, Z; Zheng, B | 1 |
| Maddon, PJ; Olson, WC | 1 |
| Alespeiti, G; Debnath, AK; He, Y; Zhao, Q | 1 |
| Clapham, PR; Dorr, P; Perros, M; Peters, PJ; Sullivan, WM; Willey, S | 1 |
| Ariën, KK; Arts, EJ; Colebunders, RL; Gali, Y; Troyer, RM; Vanham, G | 1 |
| van der Ryst, E; Westby, M | 1 |
| Carnec, X; Dragic, T; Kajumo, F; Safarian, D; Tsamis, F | 1 |
| Blish, CA; Mandaliya, K; Mosier, DE; Nedellec, R; Overbaugh, J | 1 |
| Armand-Ugón, M; Clotet, B; Esté, JA; Moncunill, G; Pauls, E | 1 |
| Ackerson, CJ; Ballard, TE; Bowman, MC; Feldheim, DL; Margolis, DM; Melander, C | 1 |
| Cao, Y; Chen, KX; Huang, XQ; Ji, RY; Jiang, HL; Luo, XM; Pei, G | 1 |
3 review(s) available for tak 779 and HIV Infections
| Article | Year |
|---|---|
[Viral entry as therapeutic target. Current situation of entry inhibitors].
Topics: Adult; Amides; Benzoates; CCR5 Receptor Antagonists; CD4 Antigens; Chemokines, CC; Chemokines, CXC; Clinical Trials as Topic; Cyclohexanes; Diketopiperazines; Drug Design; env Gene Products, Human Immunodeficiency Virus; HIV; HIV Fusion Inhibitors; HIV Infections; Humans; Maraviroc; Membrane Fusion; Models, Molecular; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Spiro Compounds; Structure-Activity Relationship; Triazoles; Virus Attachment; Virus Internalization | 2008 |
Resistance to HIV-1 entry inhibitors.
Topics: Amides; Anti-HIV Agents; Benzylamines; CD4 Immunoadhesins; Cyclams; Drug Resistance, Viral; Enfuvirtide; Heterocyclic Compounds; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Peptide Fragments; Piperazines; Quaternary Ammonium Compounds | 2003 |
CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.
Topics: Amides; Anti-HIV Agents; Antiviral Agents; CCR5 Receptor Antagonists; Clinical Trials as Topic; HIV Infections; HIV-1; Humans; Quaternary Ammonium Compounds | 2005 |
1 trial(s) available for tak 779 and HIV Infections
| Article | Year |
|---|---|
HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Kinetics; Molecular Sequence Data; Mutation; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Virus Internalization | 2012 |
17 other study(ies) available for tak 779 and HIV Infections
| Article | Year |
|---|---|
Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652.
Topics: Amino Acid Sequence; Anti-HIV Agents; CCR5 Receptor Antagonists; Cells, Cultured; Cytopathogenic Effect, Viral; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Imidazoles; Leukocytes, Mononuclear; Molecular Sequence Data; Sulfoxides; Virus Replication | 2007 |
Ex vivo comparison of microbicide efficacies for preventing HIV-1 genomic integration in intraepithelial vaginal cells.
Topics: Adult; Anti-HIV Agents; Benzothiepins; Cells, Cultured; Enfuvirtide; Female; Flow Cytometry; Genotype; HIV Envelope Protein gp41; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; In Vitro Techniques; Microscopy, Confocal; Peptide Fragments; Polymerase Chain Reaction; Virus Integration | 2010 |
Role of Tunneling Nanotube-like Structures during the Early Events of HIV Infection: Novel Features of Tissue Compartmentalization and Mechanism of HIV Spread.
Topics: Amides; Animals; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Disease Models, Animal; Hematopoietic Stem Cell Transplantation; HIV Infections; HIV-1; Humans; Interleukin Receptor Common gamma Subunit; Mice; Mice, Knockout; Quaternary Ammonium Compounds; Transplantation Chimera; Viral Load; Virus Integration; Virus Internalization; Virus Replication | 2020 |
Fusion Stage of HIV-1 Entry Depends on Virus-Induced Cell Surface Exposure of Phosphatidylserine.
Topics: Amides; Anoctamins; Antibodies, Monoclonal; Benzylamines; Calcium; CD4 Antigens; Cell Line; Cell Membrane; Cyclams; HEK293 Cells; HeLa Cells; Heterocyclic Compounds; HIV Infections; HIV-1; Host-Pathogen Interactions; Humans; Membrane Fusion; Phosphatidylserines; Phospholipid Transfer Proteins; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Signal Transduction; Viral Envelope Proteins; Virus Activation; Virus Attachment; Virus Internalization; Virus Replication | 2017 |
Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.
Topics: Amides; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cell Line, Tumor; Cells, Cultured; Chemokine CCL5; Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Recombinant Fusion Proteins; Transfection; Viral Load | 2009 |
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Topics: Amides; Amino Acid Sequence; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Drug Resistance, Viral; Evolution, Molecular; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Maraviroc; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Peptide Fragments; Piperazines; Pyrimidines; Quaternary Ammonium Compounds; Receptors, CCR5; Triazoles | 2010 |
HIV-1 clade C envelopes obtained from late stage symptomatic Indian patients varied in their ability towards relative CD4 usages and sensitivity to CCR5 antagonist TAK-779.
Topics: Amides; Anti-HIV Agents; CD4 Antigens; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; India; Molecular Sequence Data; Polymorphism, Genetic; Protein Binding; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, HIV; Sequence Analysis, DNA; Virus Internalization | 2011 |
Baseline susceptibility of primary HIV-2 to entry inhibitors.
Topics: Amides; Anti-HIV Agents; CCR5 Receptor Antagonists; Cyclohexanes; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV-1; HIV-2; Humans; Inhibitory Concentration 50; Male; Maraviroc; Microbial Sensitivity Tests; Peptide Fragments; Quaternary Ammonium Compounds; Triazoles | 2012 |
CCR5 antagonist TD-0680 uses a novel mechanism for enhanced potency against HIV-1 entry, cell-mediated infection, and a resistant variant.
Topics: Amides; Anti-HIV Agents; Binding Sites; CCR5 Receptor Antagonists; Cell Line; Cyclohexanes; HIV Infections; HIV-1; Humans; Maraviroc; Protein Structure, Secondary; Quaternary Ammonium Compounds; Receptors, CCR5; Sulfonamides; Triazoles; Tropanes; Virus Internalization; Virus Replication | 2012 |
A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5.
Topics: Amides; Animals; Anti-HIV Agents; Benzylamines; CCR5 Receptor Antagonists; CD4 Antigens; Cell Line; Cyclams; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Protein Conformation; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Virulence; Virus Replication | 2004 |
Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density.
Topics: Amides; CCR5 Receptor Antagonists; CD4 Antigens; Cell Line; Chemokine CCL5; Down-Regulation; HIV Infections; HIV-1; HIV-2; Humans; Macrophages; Monocytes; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, Cell Surface; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus | 2005 |
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time.
Topics: Amides; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cells, Cultured; Coculture Techniques; Dendritic Cells; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Phylogeny; Quaternary Ammonium Compounds; Viral Load; Virulence; Virus Replication | 2005 |
An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry.
Topics: Amides; Anti-HIV Agents; Antibodies, Monoclonal; CCR5 Receptor Antagonists; Cyclic N-Oxides; Drug Synergism; HeLa Cells; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; In Vitro Techniques; Oximes; Peptide Fragments; Piperidines; Pyridines; Quaternary Ammonium Compounds; Receptors, CCR5; Recombinant Proteins | 2006 |
HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
Topics: Amides; Antibodies, Monoclonal; Antibodies, Viral; CCR5 Receptor Antagonists; CD4 Antigens; Chemokine CCL5; Female; HIV Antigens; HIV Envelope Protein gp120; HIV Envelope Protein gp160; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Kenya; Neutralization Tests; Phylogeny; Quaternary Ammonium Compounds; Receptors, CCR5; Viral Envelope Proteins | 2007 |
HIV-1 escape to CCR5 coreceptor antagonism through selection of CXCR4-using variants in vitro.
Topics: Amides; Amino Acid Sequence; Benzylamines; CCR5 Receptor Antagonists; Cell Line, Transformed; Cell Line, Tumor; Cells, Cultured; Cyclams; Evolution, Molecular; Genetic Variation; Heterocyclic Compounds; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Molecular Sequence Data; Peptide Fragments; Quaternary Ammonium Compounds; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Sequence Alignment; Time Factors; Virus Attachment | 2008 |
Inhibition of HIV fusion with multivalent gold nanoparticles.
Topics: Amides; Gold; HIV Fusion Inhibitors; HIV Infections; HIV-1; Metal Nanoparticles; Quaternary Ammonium Compounds | 2008 |
Building three-dimensional structures of HIV-1 coreceptor CCR5 and its interaction with antagonist TAK779 by comparative molecular modeling.
Topics: Amides; Binding Sites; CCR5 Receptor Antagonists; Computer-Aided Design; HIV Infections; HIV-1; Models, Molecular; Molecular Structure; Protein Conformation; Quaternary Ammonium Compounds; Receptors, CCR5 | 2000 |